Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Acute myeloid leukemia Stories

2013-08-13 16:26:07

- Company to Host Conference Call and Webcast at 5:00 p.m. EDT, Today, August 13, 2013 SAN DIEGO, Aug. 13, 2013 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced results for the second quarter and six months ended June 30, 2013. The company will host a conference call today to provide an operational update and discuss financial...

2013-08-13 08:30:35

Update to deliver "Re-Discovering UPI-928" presentation at the 3rd World Conference on Cancer Science and Therapy on October 21 in San Francisco RENO, Nev., Aug. 13, 2013 /PRNewswire/ -- Update Pharma, Inc. ("Update") announced that the company will make an oral presentation entitled "Re-Discovering UPI-928" at the 3(rd) World Conference on Cancer Science and Therapy on October 21, 2013 in San Francisco, CA. Dr. John Rothman, CEO, will give an overview of the history of UPI-928 and...

2013-08-06 16:28:45

SAN DIEGO, Aug. 6, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced that it will report second quarter 2013 operational results after closing of the NASDAQ Global Market on August 13, 2013. Michael Martino, president and chief executive officer, will host a conference call to provide a business update at 5 p.m. EDT (2...

2013-08-05 08:27:00

- Results published in the British Journal of Hematology - JERUSALEM, Aug. 5, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced today that BL-8040 has been shown in pre-clinical trials to be effective for the treatment of thrombocytopenia, or reduced platelet production. (Logo: http://photos.prnewswire.com/prnh/20130730/630769) The findings were published in the British Journal of Hematology, a leading journal in the...

2013-07-08 12:28:47

CINCINNATI, July 8, 2013 /PRNewswire-USNewswire/ -- Scientists have successfully targeted a malfunctioning immune system enzyme to kill diseased cells from patients with myelodysplastic syndrome (MDS) - a blood disorder and precursor to leukemia. (Logo: http://photos.prnewswire.com/prnh/20110406/MM79025LOGO) Reporting their results July 8 in Cancer Cell, researchers say their successful laboratory tests in human MDS cells and mouse models of MDS provide a molecular target for...

2013-07-03 16:22:44

SAN DIEGO, July 3, 2013 /PRNewswire/ -- Ambit Biosciences Corporation (Nasdaq: AMBI) announced today that Michael Martino, president and CEO, is scheduled to present a company overview at the 8(th) Annual JMP Securities Healthcare Conference. Mr. Martino's presentation is scheduled to take place at 9:30 a.m. EDT on Wednesday, July 10, at the St. Regis New York. A live webcast of the presentation will be accessible in the investors section of the company's website, www.ambitbio.com,...

2013-06-28 08:23:47

SAN DIEGO, June 28, 2013 /PRNewswire/ -- Ambit Biosciences Corporation (Nasdaq: AMBI) announced today that the company will be added to the Russell MicroCap® Index, effective at close of business on June 28, 2013. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. Russell calculates more than 700,000 benchmarks daily covering approximately 98 percent of the investable...

2013-06-26 08:31:40

Preclinical Study Results Published in the journal Blood Show Efficacy of DOT1L Inhibitor in Animal Models CAMBRIDGE, Mass., June 26, 2013 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the publication of data on the company's clinical candidate EPZ-5676, a potent and selective small-molecule inhibitor of DOT1L, a histone...

2013-06-26 08:31:25

SAN DIEGO, June 26, 2013 /PRNewswire/ -- Ambit Biosciences Corporation (Nasdaq: AMBI) announced today data from the Phase 2 ACE study of quizartinib (AC220), a FLT3 inhibitor, were featured in multiple presentations at the 18(th) Congress of the European Hematology Association in Stockholm, Sweden. Data presented included analyses of patients with relapsed or refractory acute myeloid leukemia (AML) from a Phase 2 clinical trial of quizartinib as monotherapy. In the study,...

2013-06-25 04:21:15

SEATTLE, June 25, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today issued the following statement regarding the notification of the U.S. Food and Drug Administration (the "FDA") partial clinical hold on tosedostat (IND 075503), the Company's aminopeptidase inhibitor under development for the treatment of blood-related cancers, that is being studied in an investigator-sponsored trial and not by CTI. CTI's primary development programs are the ongoing...